ArticleFrontiers in medicine2026
Gut microbiome diversity, genus-level variation, and associations with clinical features in critically ill patients.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota alterations are common in critical illness, but differences between critically ill patients with and without sepsis and their clinical relevance remain incompletely understood. We investigated gut microbial diversity, genus-level differences and their associations with inflammatory profiles and clinical outcomes in critically ill patients. Methods: This single-centre case-control study enrolled adult critically ill patients grouped by Sepsis-3 criteria. Gut microbiota was profiled by 16S rRNA sequencing. The primary M2 model, adjusted for age, intra-abdominal infection, pre-sampling anti-anaerobic antibiotic exposure, APACHE II score, and chronic kidney disease, was used for all adjusted analyses. Alpha diversity was analyzed with HC3-robust linear regression; beta diversity with PERMANOVA, PERMDISP, and dbRDA. Genus-level primary discovery used Wilcoxon rank-sum with Benjamini-Hochberg FDR and |log2 fold change| threshold. Complementary sensitivity analyses used fully adjusted MaAsLin2 and ANCOM-BC2 with pseudo-count sensitivity. Associations of the four Wilcoxon-identified genera with clinical variables were assessed via partial Spearman correlations, logistic regression, and longitudinal mixed-effects models. Results: Of 103 participants, 68 had sepsis and 35 did not. After M2 adjustment, Shannon, Simpson, and Pielou evenness were lower in sepsis ( Conclusions: Sepsis was associated with lower values for selected alpha-diversity measures, whereas differences in overall community composition were modest. Four genera met the primary FDR- and effect-size-adjusted Wilcoxon criteria, but genus-level differences were not consistently supported across Wilcoxon, ANCOM-BC2 and MaAsLin2, indicating these are exploratory signals rather than confirmed candidates. Associations with clinical features and inflammatory markers were limited; therefore, these findings should be considered exploratory and validated using multiple analytical approaches in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.